Eli Lilly announced breakthrough results for its experimental weight-loss pill orforglipron
Eli Lilly announced breakthrough results for its experimental weight-loss pill orforglipron, which demonstrated effectiveness comparable to injectable treatments in a recent clinical trial. Shares surged following the news, positioning Lilly to potentially dominate the rapidly expanding obesity medication market.
Patients in the 40-week trial lost approximately 16 pounds (7.9% of body weight) while taking orforglipron, outperforming the 6% weight loss typically seen with Novo Nordisk’s injectable Ozempic. The pill also reduced blood sugar levels by an average of 1.3%, though this fell short of Ozempic’s 2.1% reduction.
“The engines of oral weight management are being developed in the United States,” said Chief Scientific Officer Dan Skovronsky, noting that patients had not yet reached a weight plateau when the study concluded, suggesting potential for greater long-term weight reduction.
The announcement sent Lilly shares up as much as 13%, while competitors saw significant declines – Novo Nordisk dropped 7.8% and Hims & Hers Health fell 7.2%.
This development represents a major advancement in obesity treatment, as oral medications are considered the next frontier in a market projected to reach $130 billion by decade’s end. Lilly plans to submit orforglipron for regulatory approval for weight management by late 2025, with diabetes applications following in 2026.
Eli Lilly (D1)
The stock is trading around the 61.8% Fibonacci retracement level. The RSI is on the verge of forming a higher high, which would confirm a bullish divergence, while the MACD is widening following a bullish crossover.
The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in your favor. Please ensure you fully understand the risks involved, taking into account investments objectives and level of experience, before trading and, if necessary, seek independent advice.
